Massberg Steffen, Konrad Ildiko, Bültmann Andreas, Schulz Christian, Münch Götz, Peluso Mario, Lorenz Michael, Schneider Simon, Besta Felicitas, Müller Iris, Hu Bin, Langer Harald, Kremmer Elisabeth, Rudelius Martina, Heinzmann Ulrich, Ungerer Martin, Gawaz Meinrad
Klinikum rechts der Isar, 1. Medizinische Klinik, Technische Universität München, D-81675 München, Germany.
FASEB J. 2004 Feb;18(2):397-9. doi: 10.1096/fj.03-0464fje. Epub 2003 Dec 4.
Platelet-collagen interactions play a fundamental role in the process of arterial thrombosis. The major platelet collagen receptor is the glycoprotein VI (GPVI). Here, we determined the effects of a soluble dimeric form of GPVI on platelet adhesion in vitro and in vivo. We fused the extracellular domain of GPVI with the human immunoglobulin Fc domain. The soluble dimeric form of GPVI (GPVI-Fc) specifically bound to immobilized collagen. Binding of GPVI-Fc to collagen was inhibited competitively by soluble GPVI-Fc, but not control Fc lacking the external GPVI domain. GPVI-Fc inhibited the adhesion of CHO cells that stably express human GPVI and of platelets on collagen and attenuated thrombus formation under shear conditions in vitro. To test the effects of GPVI-Fc in vivo, arterial thrombosis was induced in the mouse carotid artery, and platelet-vessel wall interactions were visualized by intravital fluorescence microscopy. Infusion of GPVI-Fc but not of control Fc virtually abolished stable arrest and aggregation of platelets following vascular injury. Importantly, GPVI-Fc but not control Fc, was detected at areas of vascular injury. These findings further substantiate the critical role of the collagen receptor GPVI in the initiation of thrombus formation at sites of vascular injury and identify soluble GPVI as a promising antithrombotic strategy.
血小板与胶原蛋白的相互作用在动脉血栓形成过程中起着至关重要的作用。主要的血小板胶原蛋白受体是糖蛋白VI(GPVI)。在此,我们确定了可溶性二聚体形式的GPVI在体外和体内对血小板黏附的影响。我们将GPVI的胞外结构域与人免疫球蛋白Fc结构域融合。可溶性二聚体形式的GPVI(GPVI-Fc)特异性结合固定化的胶原蛋白。可溶性GPVI-Fc竞争性抑制GPVI-Fc与胶原蛋白的结合,但缺乏外部GPVI结构域的对照Fc则无此作用。GPVI-Fc抑制稳定表达人GPVI的CHO细胞以及血小板在胶原蛋白上的黏附,并在体外剪切条件下减弱血栓形成。为了测试GPVI-Fc在体内的作用,在小鼠颈动脉诱导动脉血栓形成,并通过活体荧光显微镜观察血小板与血管壁的相互作用。输注GPVI-Fc而非对照Fc实际上消除了血管损伤后血小板的稳定停滞和聚集。重要的是,在血管损伤部位检测到了GPVI-Fc而非对照Fc。这些发现进一步证实了胶原蛋白受体GPVI在血管损伤部位血栓形成起始中的关键作用,并确定可溶性GPVI是一种有前景的抗血栓策略。